4//SEC Filing
Espinoza Octavio 4
Accession 0002001011-25-000028
CIK 0000886163other
Filed
May 12, 8:00 PM ET
Accepted
May 13, 8:04 PM ET
Size
6.8 KB
Accession
0002001011-25-000028
Insider Transaction Report
Form 4
Espinoza Octavio
Chief Financial Officer
Transactions
- Purchase
Common Stock
2025-05-09$104.40/sh+500$52,200→ 27,932 total - Purchase
Common Stock
2025-05-09$103.89/sh+1,000$103,890→ 27,432 total
Footnotes (2)
- [F1]The reporting person's purchase of Ligand Pharmaceuticals Incorporated ("Ligand") common stock reported herein might be deemed matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,500 shares, with the reporting person's sale of 2,104 shares of Ligand common stock at the highest price of $116.71 per share on December 23, 2024. Accordingly, the reporting person has paid to Ligand, $18,975, representing the full amount of any profit realized if this were to be deemed to be a short-swing transaction.
- [F2]The total includes 69 shares acquired on December 31, 2024, through the Issuer's Employee Stock Purchase Plan (ESPP).
Documents
Issuer
LIGAND PHARMACEUTICALS INC
CIK 0000886163
Entity typeother
Related Parties
1- filerCIK 0001905248
Filing Metadata
- Form type
- 4
- Filed
- May 12, 8:00 PM ET
- Accepted
- May 13, 8:04 PM ET
- Size
- 6.8 KB